Premier Biomedical (BIEI) 0.1100 $BIEI
PBI Signs Contract with UTEP for Cancer Treatment Methodology Protocol Shown to Greatly Increase Survival and Prevention of Breast Cancer Metastasis
ACCESSWIRE - Thu Apr 16, 7:04AM CDT
EL PASO, TX / ACCESSWIRE / April 16, 2015 / Premier Biomedical Inc. (OTCQB:BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.
Premier Biomedical files with the US FDA for patented drug Feldetrex for treating Fibromyalgia
M2 - Wed Jan 21, 5:53AM CST
Medical treatment company Premier Biomedical (OTC BB:BIEI) said on Tuesday that it has submitted documents to the US Food and Drug Administration for both clinical studies and eventual marketing approval for the patented drug combination of Feldetrex for treating fibromyalgia.
Premier Biomedical Files Initial FDA Submission for Fibromyalgia Treatment
Business Wire - Tue Jan 20, 7:02AM CST
Premier Biomedical, Inc. (OTCBB: BIEI) announced that they intend to nationally sell an exclusively licensed and patented drug treatment for fibromyalgia. Premier is submitting documents to the Food and Drug Administration to discuss agency requirements for both clinical studies and eventual marketing approval for this patented drug combination. The drug, Feldetrex(R), was issued a patent for its unique combination of FDA approved compounds, in October of 2014.
Premier Biomedical Files Patent and FDA Application for Ebola Virus Treatment
ACCESSWIRE - Wed Jan 07, 7:00AM CST
El Paso, TX / ACCESSWIRE / January 7, 2015 / Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014. Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.
OxBridge Research Publishes a Comprehensive Research Report on Premier Biomedical
Business Wire - Thu Nov 13, 9:00AM CST
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that the investment research company, OxBridge Research, has concluded and published its in-depth study of Premier Biomedical, Inc.
Premier Biomedical Announces the Addition of Dr. Patricio Reyes to Scientific Advisory Board
Business Wire - Mon Oct 06, 7:00AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) announced the addition of Dr. Patricio F. Reyes to their Scientific Advisory Board effective immediately. Dr. Reyes will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.
Premier Biomedical Announces the Addition of K. Adam Dubov, Esq. to Scientific Advisory Board
Business Wire - Mon Sep 22, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI" announced the addition of K. Adam Dubov to their Scientific Advisory Board effective immediately. Mr. Dubov will report to the Chairman of the Scientific Advisory Board, and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.
Premier Biomedical Announced the Addition of Dr David Vigerust to Their Scientific Advisory Board
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Premier Biomedical, Inc. (OTC-BB: "BIEI" announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder.
Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs" are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed.
PFE: 33.99 (+0.05), BMY: 67.64 (+0.19)
Promising Medical Breakthroughs by Premier Biomedical, Inc.(BIEI)
GlobeNewswire - Tue Jul 29, 6:47AM CDT
Uptick Newswire sat with President and CEO of Premier Biomedical Inc., Mr. William A. Hartman, to get the scoop on their medical miracles that are stretching scientific limits. Based in El Paso Texas., Premier Biomedical Inc. is working closely with the US Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) in high hopes of creating a brighter future for those that have little hope of seeing that future today.
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC" has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August.
PFE: 33.99 (+0.05), BYM: 14.00 (+0.03)
Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and Rose as Investor Relations Council
GlobeNewswire - Thu Jul 24, 6:47AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI" a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that it has retained the investor relations firm Porter, LeVay and Rose to represent it and to implement its communications strategies.
Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia
Business Wire - Mon Jun 30, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI" a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer's disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication "Feldetrex (TM)", which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future.
Premier Biomedical Releases Anti-CTLA4 Market Study
Business Wire - Tue Jun 17, 7:02AM CDT
Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis ("MS", and traumatic brain injury ("TBI", today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting ("PBG" discussing its breast cancer treatment.
PBI Signs Contract with UTEP for Cancer Treatment Methodology Protocol Shown to Greatly Increase Survival and Prevention of Breast Cancer Metastasis
ACCESSWIRE - Thu Apr 16, 7:04AM CDT
EL PASO, TX / ACCESSWIRE / April 16, 2015 / Premier Biomedical Inc. (OTCQB:BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.
Premier Biomedical files with the US FDA for patented drug Feldetrex for treating Fibromyalgia
M2 - Wed Jan 21, 5:53AM CST
Medical treatment company Premier Biomedical (OTC BB:BIEI) said on Tuesday that it has submitted documents to the US Food and Drug Administration for both clinical studies and eventual marketing approval for the patented drug combination of Feldetrex for treating fibromyalgia.
Premier Biomedical Files Initial FDA Submission for Fibromyalgia Treatment
Business Wire - Tue Jan 20, 7:02AM CST
Premier Biomedical, Inc. (OTCBB: BIEI) announced that they intend to nationally sell an exclusively licensed and patented drug treatment for fibromyalgia. Premier is submitting documents to the Food and Drug Administration to discuss agency requirements for both clinical studies and eventual marketing approval for this patented drug combination. The drug, Feldetrex(R), was issued a patent for its unique combination of FDA approved compounds, in October of 2014.
Premier Biomedical Files Patent and FDA Application for Ebola Virus Treatment
ACCESSWIRE - Wed Jan 07, 7:00AM CST
El Paso, TX / ACCESSWIRE / January 7, 2015 / Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014. Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.
OxBridge Research Publishes a Comprehensive Research Report on Premier Biomedical
Business Wire - Thu Nov 13, 9:00AM CST
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that the investment research company, OxBridge Research, has concluded and published its in-depth study of Premier Biomedical, Inc. Premier Biomedical Announces the Addition of Dr. Patricio Reyes to Scientific Advisory Board
Business Wire - Mon Oct 06, 7:00AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) announced the addition of Dr. Patricio F. Reyes to their Scientific Advisory Board effective immediately. Dr. Reyes will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.
Premier Biomedical Announces the Addition of K. Adam Dubov, Esq. to Scientific Advisory Board
Business Wire - Mon Sep 22, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
announced the addition of K. Adam Dubov to their Scientific Advisory Board effective immediately. Mr. Dubov will report to the Chairman of the Scientific Advisory Board, and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman. Premier Biomedical Announced the Addition of Dr David Vigerust to Their Scientific Advisory Board
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Premier Biomedical, Inc. (OTC-BB: "BIEI"
announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder. Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs"
are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed. PFE: 33.99 (+0.05), BMY: 67.64 (+0.19)
Promising Medical Breakthroughs by Premier Biomedical, Inc.(BIEI)
GlobeNewswire - Tue Jul 29, 6:47AM CDT
Uptick Newswire sat with President and CEO of Premier Biomedical Inc., Mr. William A. Hartman, to get the scoop on their medical miracles that are stretching scientific limits. Based in El Paso Texas., Premier Biomedical Inc. is working closely with the US Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) in high hopes of creating a brighter future for those that have little hope of seeing that future today.
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC"
has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August. PFE: 33.99 (+0.05), BYM: 14.00 (+0.03)
Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and Rose as Investor Relations Council
GlobeNewswire - Thu Jul 24, 6:47AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that it has retained the investor relations firm Porter, LeVay and Rose to represent it and to implement its communications strategies. Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia
Business Wire - Mon Jun 30, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer's disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication "Feldetrex (TM)", which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future. Premier Biomedical Releases Anti-CTLA4 Market Study
Business Wire - Tue Jun 17, 7:02AM CDT
Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis ("MS"
, and traumatic brain injury ("TBI", today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting ("PBG" discussing its breast cancer treatment. 
